Telomir Pharmaceuticals Corp (TELO) - מקדם חוב לטווח ארוך להון

The current long-term debt-to-equity ratio demonstrates the financial stability of Telomir Pharmaceuticals (TELO), which focuses on tissue regeneration and telomere biology. The value 0.00 reflects the metric's balance, while the venture R&D effect awaits molecule validation for licensing. Meanwhile, rising laboratory expenses are increasing development costs, temporarily precluding the commercial scaling of the business.

The lack of commercial scale in Telomir Pharmaceuticals (TELO) research is leading to an increase in unit development costs. This metric compares liabilities with maturities exceeding one year to equity to determine financial leverage. Investors evaluate this balance to distinguish real solvency from operational noise. An analysis of the long-term debt-to-equity ratio reveals the company's dependence on borrowed funds. The trend in the long-term debt-to-equity ratio confirms the business's resilience to external shocks.